Data gathered: October 23
Alternative Data for Gilead Sciences
About Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
| Price | $87.45 |
| Target Price | Sign up |
| Volume | 1,810,000 |
| Market Cap | $107B |
| Year Range | $62.11 - $88.16 |
| Dividend Yield | 3.55% |
| PE Ratio | 105.23 |
| Analyst Rating | 59% buy |
| Earnings Date | November 6 '24 |
| Industry | Biotechnology |
In the news
 |
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Signaturefd LLCOctober 23 - ETF Daily News |
 |
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Allspring Global Investments Holdings LLCOctober 23 - Biztoc.com |
|
Gilead Sciences (NASDAQ:GILD) Stock Rating Upgraded by Leerink PartnersOctober 22 - ETF Daily News |
 |
Gilead Sciences (NASDAQ:GILD) Upgraded to “Strong-Buy” at Leerink PartnrsOctober 22 - ETF Daily News |
|
Whittier Trust Co. Sells 2,834 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)October 22 - ETF Daily News |
|
Gilead Sciences (NASDAQ:GILD) Stock Rating Upgraded by Leerink PartnrsOctober 22 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 6.98B | 2.94B | 4.04B | 1.61B | 3.38B | 2.010 |
| Q1 '24 | 6.46B | 5.42B | 1.04B | -4.17B | 2.99B | -1.320 |
| Q4 '23 | 6.87B | 5.08B | 1.79B | 1.43B | 2.52B | 1.720 |
| Q3 '23 | 6.82B | 3.48B | 3.34B | 2.18B | 3.16B | 2.290 |
| Q2 '23 | 6.42B | 3.89B | 2.53B | 1.05B | 2.42B | 1.660 |
Insider Transactions View All
| Parsey Merdad filed to sell 100,189 shares at $83.8. October 2 '24 |
| Mercier Johanna filed to sell 78,127 shares at $83.3. September 13 '24 |
| Mercier Johanna filed to sell 91,559 shares at $84.2. September 13 '24 |
| Parsey Merdad filed to sell 102,189 shares at $84.5. September 13 '24 |
| Mercier Johanna filed to sell 105,466 shares at $78. August 29 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rohit Khanna Democrat |
Jun 5, 24 | Buy | $1K - $15K |
| Thomas Tuberville Republican |
May 15, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Sell | $1K - $15K |
Read more about Gilead Sciences (GILD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Gilead Sciences?
The Market Cap of Gilead Sciences is $107B.
What is Gilead Sciences' PE Ratio?
As of today, Gilead Sciences' PE (Price to Earnings) ratio is 105.23.
When does Gilead Sciences report earnings?
Gilead Sciences will report its next earnings on November 6 '24.
What is the current stock price of Gilead Sciences?
Currently, the price of one share of Gilead Sciences stock is $87.45.
How can I analyze the GILD stock price chart for investment decisions?
The GILD stock price chart above provides a comprehensive visual representation of Gilead Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gilead Sciences shares. Our platform offers an up-to-date GILD stock price chart, along with technical data analysis and alternative data insights.
Does GILD offer dividends to its shareholders?
Yes, Gilead Sciences (GILD) offers dividends to its shareholders, with a dividend yield of 3.55%. This dividend yield represents Gilead Sciences' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Gilead Sciences in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Gilead Sciences?
Some of the similar stocks of Gilead Sciences are Amgen, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.